| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Feb, 2026 | Feb, 2026 | Feb, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -61,690 | -47,260 | 0 | 0 | 0 |
| Net Income Growth | -30.53% | unch | unch | unch | unch |
Sionna Therapeutics Inc
(SION)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Sionna Therapeutics Inc. is a clinical-stage biopharmaceutical company by developing novel medicines that normalize the function of the CFTR protein. Sionna Therapeutics Inc. is based in BOSTON.
Fiscal Year End Date: 12/31